Update in inflammatory bowel disease

Australian Family Physician

Volumn 38, Issue 12, 2009, Pages 956-961

  Morrison, Graham ^a   Headon, Belinda ^a   Gibson, Peter ^a,b  

^a BOX HILL HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

AUSTRALIA; CROHN DISEASE; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; AUSTRALIA; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 77953244367     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:V1-16.
2. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85.
4. Lichenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87.
5. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiological study. Inflamm Bowel Dis 2006;12;936-43.
6. Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: A prospective population-based Australian incidence study. Inflamm Bowel Dis 2009; in press.
7. Goh KL. Inflammatory bowel disease: Incidence and prevalence across Asia. In: Emerging issues in inflammatory bowel diseases. Falk symposium 151. Springer Publishing, 2006.
8. Access Economics. Working with IBD, June 2009. Available at www.crohnsandcolitis.com.au.
9. Wong A, Bass D. Laboratory evaluation of inflammatory bowel disease. Curr Opin Paediatr 2008;20:566-70.
10. Bruining DH, Loftus EV. Current and future diagnostic approaches: From serologies to imaging. Curr Gastroenterol Rep 2007;9:489-6.
11. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41:306-11.
12. Thorlacius H, Toth E. Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:911-7.
13. Moss A, Parrish FJ, Irving PM. Gibson PR. Quality, clinical impact and tolerance of CT enteroclysis in patients with suspected small bowel disease. Intern Med J 2008; Nov 11:Epub ahead of print.
14. Lawrance IC, Welman CJ, Shipman P, Murray K. Correlation of MRI-determined Update in inflammatory bowel disease THEME small bowel Crohn's disease categories with medical response and surgical pathology. World J Gastroenterol 2009;15:3367-75.
15. Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-aminosalicylic acid (mesalazine) use in Crohn's disease: A survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 2007;13:1009-15.
16. James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: Frequently asked questions analysis. Intern Med J 2008;38:114-9.
17. Kane SV. Systematic review: Adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-85.
18. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902.
19. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: A double-blind, double dummy, randomised non- inferiority trial. Gut 2009;58:233-40.
20. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102.
21. Andrews JM, Travis SPL, Gibson PR, Gasche C. Systematic review: Concurrent therapy with 5-ASA and immunomodulators in IBD. Aliment Pharmacol Ther 2009;9:459-69.
22. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57.
23. Nathan DM, Iser JH, Gibson PR. A single centre experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: A case for subcutaneous administration. J Gastroenterol Hepatol 2008;23:954-8.
24. Behm BW, Bickston SJ. Tumour necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;(1):CD006893.
25. Grimpen F, Pavli P. Advances in the management of inflammatory bowel disease. Int Med J 2009; in press.
26. Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: Appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-29.
27. Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: Topdown or bottom-up? Curr Opin Gatsroenterol 2007;23:395-9.
28. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
29. Hommes D, Baert F, Van Assche G, et al. A randomized control trial evaluating the ideal medical management for Crohn's disease (CD): Top-down versus step-up strategies. Gastroenterology 2005;128(Suppl 2):A577.
30. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;5:621-30.
31. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;19:2275-85.
32. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-6.
33. ACOG. Committee on Practice Bulletins-Gynaecology. Cervical cytology screening. Practice bulletin number 45. Obstet Gynecol 2003;102:417-27.
34. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;12:1639-41.
35. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
36. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1575-84.
37. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anaemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-307.
38. Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of poorly absorbed short chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohn's Colitis 2009;3:8-14.